scholarly journals The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease

2017 ◽  
Vol 46 (8) ◽  
pp. 731-740 ◽  
Author(s):  
H. Rao ◽  
E. Wu ◽  
S. Fu ◽  
M. Yang ◽  
B. Feng ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Chinese Patients ◽  
Rapid Progression ◽  
Advanced Liver Disease ◽  
Truncal Obesity ◽  
Obesity And Diabetes

scholarly journals Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease

Medicine ◽  
2017 ◽  
Vol 96 (6) ◽  
pp. e6128 ◽  
Author(s):  
Christine Y. Chang ◽  
Pauline Nguyen ◽  
An Le ◽  
Changqing Zhao ◽  
Aijaz Ahmed ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Asian Americans ◽  
Real World ◽  
Advanced Liver Disease ◽  
Direct Acting Antiviral ◽  
Antiviral Therapies ◽  
Direct Acting

Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease

2014 ◽  
Vol 26 (8) ◽  
pp. 836-845 ◽  
Author(s):  
Benjamin Maasoumy ◽  
Kerstin Port ◽  
Katja Deterding ◽  
Christoph Höner zu Siederdissen ◽  
Antoaneta A. Markova ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Protease Inhibitor ◽  
Triple Therapy ◽  
Chronic Hepatitis C ◽  
Real World ◽  
Safety Profile ◽  
Advanced Liver Disease ◽  
Limited Effectiveness

scholarly journals Advanced liver disease in Russian children and adolescents with chronic hepatitis C

2019 ◽  
Vol 26 (7) ◽  
pp. 881-892 ◽  
Author(s):  
Anna Turkova ◽  
Galina V. Volynets ◽  
Siobhan Crichton ◽  
Tamara A. Skvortsova ◽  
Victoria N. Panfilova ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Children And Adolescents ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease

A Review on the Use of Eltrombopag in Patients with Advanced Liver Disease

2009 ◽  
Vol 1 ◽  
pp. CMT.S2267
Author(s):  
Edoardo G. Giannini ◽  
Alfredo Greco ◽  
Vincenzo Savarino
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Pegylated Interferon ◽  
Severe Thrombocytopenia ◽  
Current Standard ◽  
Advanced Liver Disease ◽  
Orally Bioavailable

Thrombocytopenia is the most common hematological abnormality in patients with chronic, advanced liver disease. In these patients, the presence of severe thrombocytopenia is an obstacle to the performance of invasive diagnostic and therapeutic procedures, and the current standard treatment for these patients is platelet transfusions, a remedy whose characteristics are far from being ideal. Furthermore, thrombocytopenia in patients with chronic hepatitis C virus infection may render the patients ineligible to antiviral treatment or may limit its efficacy because of premature discontinuation. Although the cause of thrombocytopenia in patients with chronic liver disease is likely multi-factorial, decreased thrombopoietin production by the liver undoubtedly plays a significant role. In this regard, eltrombopag, a non-peptide, orally bioavailable thrombopoietin receptor agonist has been shown to safely increase platelet count in a dose-dependent fashion in both healthy subjects and thrombocytopenic patients with chronic hepatitis C. Furthermore, in this latter group of patients, it has been shown to be superior to placebo in counteracting the myelosuppressive effect of short-term pegylated interferon treatment.

Interleukin-11 in patients with chronic hepatitis C and advanced liver disease who have been nonresponsive to antiviral therapy

2003 ◽  
Vol 124 (4) ◽  
pp. A768
Author(s):  
Eric J. Lawitz ◽  
Thomas Casey ◽  
Norma S. Cantu
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease ◽  
Interleukin 11

SAT-240-Metabolic liver function improves 12 weeks after successful sofosbuvir-based direct-acting antiviral therapy in patients with chronic hepatitis C and advanced liver disease

2019 ◽  
Vol 70 (1) ◽  
pp. e738
Author(s):  
Tea Lund Laursen ◽  
Cecilie Brøckner Siggard ◽  
Konstantin Kazankov ◽  
Thomas Damgaard Sandahl ◽  
Holger Jon Møller ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Liver Function ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease ◽  
Direct Acting Antiviral ◽  
Metabolic Liver Function ◽  
Direct Acting

SVR reduces ethnic disparities in progression to advanced liver disease in patients with chronic hepatitis C

2017 ◽  
Vol 66 (1) ◽  
pp. S283-S284
Author(s):  
A.K. Le ◽  
C. Zhao ◽  
J. Hoang ◽  
L.A. Yasukawa ◽  
J. Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Ethnic Disparities ◽  
Advanced Liver Disease

Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients

2017 ◽  
Vol 206 (2) ◽  
pp. 165-174 ◽  
Author(s):  
Abdolvahab Alborzi ◽  
Tayebeh Hashempour ◽  
Javad Moayedi ◽  
Zahra Musavi ◽  
Gholamreza Pouladfar ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Serum Level ◽  
Chronic Hepatitis C ◽  
Advanced Liver Disease ◽  
Chronic Hepatitis C Patients
Sign in / Sign up

Export Citation Format

Share Document